India, May 23 -- Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration.
The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit.
The Buprenorphine HCl Injection is indicated for the management of pain requiring an opioid analgesic and for which alternate treatments are inadequate. The injection is a clear, sterile, injectable agonist-antagonist analgesic intended for intravenous or IV or intramuscular or IM administration.
Labetalol HCl Injection is indicated for contro...